Pedro Barata speaks with Tian Zhang about the PDIGREE phase III adaptive trial. This cooperative group study enrolled over 1,000 patients across 46 states over five years, representing a collaborative ...

Zachary Klaassen interviews Nicholas James about applying the ArteraAI prostate test to high-risk M0 prostate cancer patients from STAMPEDE. Dr. James explains how they analyzed M0 patients receiving ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, was host to the Session State of the Art Lecture: Personalizing treatment for patients with ...

Gianluca Giannarini argued that BCG remains the best option for high-risk non-muscle invasive bladder cancer, using "BCG" as an acronym for its key advantages: Benefit, Cost, and Grounded. BCG offers ...

(UroToday.com) The 2025 AUA annual meeting featured a radiation therapy for localized prostate cancer session and a presentation by Dr. Anne Hong discussing the safety of stabilized hyaluronic acid as ...

(UroToday.com) The 2025 AUA annual meeting featured a bladder cancer clinical trials in progress session and a presentation by Dr. Max Kates discussing PIVOT-006, a phase 3, randomized study of ...

(UroToday.com) The 2025 ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Maha Hussain discussing the clinical, environmental, genetic, and genomic profile of patients ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a kidney and bladder cancers oral abstract ...

(UroToday.com) The 2025 ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Sharon Choi discussing comprehensive genomic profiling of Black and non-Hispanic White men with ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago, IL, was host to a kidney and bladder cancers oral abstract session. Dr. Tian Zhang discussed the ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, was host to the Oral Abstract Session: Genitourinary Cancer—Prostate, Testicular, and Penile.

(UroToday.com) The 2025 ASCO annual meeting featured a prostate cancer session and a presentation by Dr. David Wise discussing a phase 1 study of gotistobart (BNT316/ONC-392) in combination with ...